Compound ID | 8
Suvratoxumab
Synonym(s): MEDI4893 | LC-10 | LC10 | LC 10
Class: Antibody
| Agent Type: | Indirect acting; Antibody; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Targets alpha toxins; improves outcome and healing process at multiple stages of skin and soft tissue infections (SSTIs) |
| Target Pathogen: | Active against Staphylococcus aureus |
| Combined with other compounds: | Yes |
| Institute where first reported: | Medimmune, USA |
| Year first mentioned: | 2012 |
| Highest developmental phase: | Phase 3 (NCT05331885) |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/472405028 |
| Guide to Pharmacology: | suvratoxumab |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.